Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Vemurafenib bulk supplier for pharma manufacturers

Vemurafenib 240 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 240 mg

Reference Brands: Zelboraf (USA/EU), Vemura (India)

Category: Oncology Cancer Care

Vemurafenib is a Oncology Cancer Care product available as Tablets in strengths 240 mg. It corresponds to the reference brands Zelboraf (USA/EU), Vemura (India). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Vemurafenib is a targeted anticancer medication used primarily for the treatment of metastatic or unresectable melanoma that carries a BRAF V600 mutation. It is a selective BRAF inhibitor that works by blocking the activity of the mutated BRAF V600E kinase, a protein involved in the MAPK signaling pathway that promotes tumor cell growth and proliferation. By inhibiting this pathway, vemurafenib helps slow down or stop the growth of cancer cells and supports better disease control in affected patients.

The drug has been approved for use in patients with BRAF-mutant melanoma and is also indicated for certain rare conditions such as Erdheim-Chester disease. In clinical practice, vemurafenib may sometimes be used in other cancers that carry BRAF mutations, including refractory non-small cell lung cancer and papillary thyroid cancer, when appropriate treatment options are limited. Clinical trials such as the BRIM studies demonstrated significant improvements in survival outcomes for patients with BRAF-mutant melanoma, which contributed to its regulatory approval.

While effective, treatment with vemurafenib may cause side effects such as skin reactions, rash, and increased sensitivity to sunlight. Because of potential risks, patients receiving this therapy require regular monitoring of liver, kidney, and heart function to ensure safe and effective treatment.

Vemurafenib — third party manufacturing & bulk supply

Vemurafenib 240 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Indicative minimum order quantity

Vemurafenib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Vemurafenib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Vemurafenib →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Vemurafenib is used for the treatment of patients with unresectable or metastatic melanoma that carries the BRAF V600 mutation. It may also be used in certain cases of other cancers where this mutation is present and targeted therapy is appropriate.

Vemurafenib is a synthetic small-molecule kinase inhibitor designed to selectively block the activity of the mutated BRAF V600 protein, which is involved in promoting the growth and survival of cancer cells.

The primary trade name of Vemurafenib is Zelboraf.

Vemurafenib (Zelboraf) was developed and is marketed by F. Hoffmann-La Roche in collaboration with Genentech.

The generic name is Vemurafenib.

The main brand name is Zelboraf.

Vemurafenib is manufactured in GMP-approved pharmaceutical facilities authorized by regulatory agencies such as the US FDA, EMA, and other national health authorities, depending on the region where the product is supplied.

Related Products

Fruquin 5 Mg (Fruquintinib)

Strength:
5 Mg

Form: Capsules

Reference Brands: Everest Bangladesh altd.

View Details
Vorinostat

Strength:
100 mg

Form: Capsules

Reference Brands: Zolinza (USA/EU), Vornat (India)

View Details
Panobinostat Lactate

Strength:
10 mg, 15 mg, 20 mg

Form: Capsules

Reference Brands: Farydak (USA/EU),

View Details
Gilteritinib

Strength:
40 mg

Form: Tablets

Reference Brands: Xospata (USA/India), LuciGil (Asia)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.